BioSystem Development Unveils AssayMAP MAb Titer Assay

BioSystem Development has released the AssayMAP MAb Titer Assay for measuring antibody product concentrations (or titers) in bioprocess samples.

Antibody titer assays are a critical bottleneck in biotherapeutic process development. Although the current ‘gold standard’ method, protein A affinity HPLC is reliable, selective, sensitive and precise, its throughput is severely limited to merely 4 – 12 samples an hour, said the company.

The AssayMAP MAb Titer assay uses exactly the same chemistry as protein A HPLC with a 100-fold increase in throughput, equivalent analytical performance and no need for specialised instrumentation.

AssayMAP cartridges, filled with POROS MabCapture A media from Life Technologies, offer rapid, small-scale parallel analysis either manually in a spin-column format or on common automation platforms and measure IgG concentration across a wide range, ideally suited for process development without a need for sample dilution, claims the company.

Scott Fulton, founder and CEO, said: “This launch is a significant milestone in the evolution of the AssayMAP platform. It is the first assay we adapted to a spin-column format that requires only common lab equipment to perform, making AssayMAP solutions readily available for researchers when investment in new instrumentation platforms is not possible.”